Brief: Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data In Mob-015 Phase 3 Study
10/12/2024 22:51
Dec 10 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO :
* CIPHER PHARMACEUTICALS PARTNER MOBERG PHARMA AB REPORTS
TOPLINE
DATA IN MOB-015 PHASE 3 STUDY
* CIPHER PHARMACEUTICALS INC - MOB-015 FAILS TO MEET PRIMARY
ENDPOINT IN PHASE 3 STUDY
Source text: urn:newsml:reuters.com:*:nCNWlJSxga
Further company coverage: CPH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million